An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens
- 24 May 2018
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 12 (12) , 1265-1272
Abstract
Background: A large Egyptian treatment program for HCV was launched in2014 after the introduction of direct-acting antiviral agents (DAAs). This program depended mainly on establishing specialized independent centres for HCV treatment. These centres represent the major strengths in the Egyptian model of care, as they provide integrated care for HCV patients and have enabled Egypt to treat more than one million patients in 3 years. The New Cairo Viral Hepatitis Treatment Center (NCVHTC) is an example of these specialized centres. Methods: The Egyptian experience in the management of HCV was evaluated by analysing the data of real-life HCV management in the NCVHTC from 2014 to 2017. Results of different treatment regimens in addition to their strengths, limitations and areas for improvement are discussed in this report. Results: A total of 7042 HCV patients have been evaluated for treatment in the NCVHTC. Among them, 5517 patients received treatment by seven different DAA regimens with excellent results. Conclusions: All regimens were highly effective at treating HCV in a real-life setting, apart from SOF/RBV, which was the least effective. A nationwide screening program and enhancing the follow-up of treated patients are the main missing pillars in the Egyptian model.Keywords
This publication has 16 references indexed in Scilit:
- Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patientsLiver International, 2016
- Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trialThe Lancet Gastroenterology & Hepatology, 2016
- Safety of direct antiviral agents in the management of hepatitis CExpert Opinion on Drug Safety, 2016
- Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real lifeJournal of Viral Hepatitis, 2016
- Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4Journal of Hepatology, 2015
- Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestryJournal of Hepatology, 2015
- Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacyJournal of Hepatology, 2014
- Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV‐genotype 4 in EgyptJournal of Viral Hepatitis, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013